Antithrombotic effect of FK506 vs cyclosporine in cardiac transplant recipients: potential implications in transplant arteriopathy.

[1]  P. Meraj,et al.  Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[2]  H. Valantine,et al.  HMG-CoA reductase inhibitors reduce transplant coronary artery disease and mortality: evidence for antigen-independent mechanisms? , 1997, Circulation.

[3]  D. Nelson,et al.  Hemostasis, fibrinolysis, and natural anticoagulation in transplant vascular sclerosis. , 1995, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[4]  Y. Sasaki,et al.  Antithrombotic effect of FK506 versus prothrombotic effect of cyclosporine in vivo. , 1995, Transplantation.

[5]  P. Libby,et al.  Human coronary transplantation-associated arteriosclerosis. Evidence for a chronic immune reaction to activated graft endothelial cells. , 1991, The American journal of pathology.

[6]  V. Fuster,et al.  Influence of Arterial Damage and Wall Shear Rate on Platelet Deposition: Ex Vivo Study in a Swine Model , 1986, Arteriosclerosis.

[7]  V. Fuster,et al.  Spontaneous and Diet‐Induced Coronary Atherosclerosis in Normal Swine and Swine with von Wiiiebrand Disease , 1985, Arteriosclerosis.

[8]  V. Fuster,et al.  Arteriosclerosis in Normal and von Willebrand Pigs: Long‐Term Prospective Study and Aortic Transplantation Study , 1982, Circulation research.

[9]  J. Squifflet,et al.  Lipoprotein patterns in renal transplant patients: a comparison between FK 506 and cyclosporine A patients. , 1998, Transplantation proceedings.

[10]  U. Naik,et al.  Cyclosporine A enhances agonist-induced aggregation of human platelets by stimulating protein phosphorylation. , 1993, Cellular & molecular biology research.